BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients: Critical Reviews in Oncology/Hematology

U. Malapelle, G. Rossi, P. Pisapia, M. Barberis, F. Buttitta, F. Castiglione, F.L. Cecere, A.M. Grimaldi, A. Iaccarino, A. Marchetti, D. Massi, D. Medicina, F. Mele, R. Minari, E. Orlando, F. Pagni, G. Palmieri, L. Righi, A. Russo, S. TommasiW. Vermi, G. Troncone

Research output: Contribution to journalArticlepeer-review

Abstract

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular predictive pathology testing is provided. © 2020 Elsevier B.V.
Original languageEnglish
JournalCrit. Rev. Oncol. Hematol.
Volume156
DOIs
Publication statusPublished - 2020

Keywords

  • BRAF
  • Lung cancer
  • Melanoma
  • Precision medicine
  • Predictive molecular pathology
  • B Raf kinase
  • cobimetinib
  • dabrafenib
  • sorafenib
  • trametinib
  • tumor marker
  • vemurafenib
  • biological marker
  • BRAF protein, human
  • BRAF gene
  • cancer combination chemotherapy
  • cancer diagnosis
  • cancer survival
  • clinical decision making
  • drug efficacy
  • gene
  • gene mutation
  • high throughput sequencing
  • human
  • immunohistochemistry
  • lung cancer
  • matrix assisted laser desorption ionization time of flight mass spectrometry
  • melanoma
  • molecular biology
  • mutational analysis
  • non small cell lung cancer
  • nonhuman
  • outcome assessment
  • overall survival
  • predictive value
  • protein function
  • pyrosequencing
  • real time polymerase chain reaction
  • Review
  • Sanger sequencing
  • genetics
  • lung tumor
  • mutation
  • Biomarkers
  • Carcinoma, Non-Small-Cell Lung
  • Humans
  • Lung Neoplasms
  • Mutation
  • Proto-Oncogene Proteins B-raf

Fingerprint

Dive into the research topics of 'BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients: Critical Reviews in Oncology/Hematology'. Together they form a unique fingerprint.

Cite this